Radiation

Ivy Brain Tumor Center Announces Promising Results of Phase 0/1 Glioblastoma Study at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Friday, April 5, 2024
Radiation, Brain, Patient, DNA, Ben, Hope, MD, AACR, Glioblastoma, ATM, Barrow Neurological Institute, Hedera, Medical imaging

Results from this study will be presented at the American Association for Cancer Research Annual Meeting and demonstrate that AZD1390 may be a potent radiosensitizer in both newly diagnosed and recurrent glioblastoma patients.

Key Points: 
  • Results from this study will be presented at the American Association for Cancer Research Annual Meeting and demonstrate that AZD1390 may be a potent radiosensitizer in both newly diagnosed and recurrent glioblastoma patients.
  • Study results show AZD1390 is well tolerated in this patient population, that the drug achieved high concentrations in patients’ tumor tissue and successfully modulates its target in this tissue.
  • Ivy Brain Tumor Center scientists and investigators will also present seven posters highlighting results from preclinical and clinical studies at the meeting.
  • This is an investigator-initiated study funded by the Ben & Catherine Ivy Foundation and Barrow Neurological Foundation.

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

Retrieved on: 
Tuesday, April 2, 2024
NBTXR3, Lung cancer, NSCLC, Patient, Observation, Cancer, Nanobiotix, NANO, Radiation, MD, University, MD Anderson Cancer Center, Safety, Pharmaceutical industry

The Phase 1 study (“Study 2020-0123”) is being conducted by The University of Texas MD Anderson Cancer Center (“MD Anderson”) as part of an ongoing strategic collaboration with Nanobiotix.

Key Points: 
  • The Phase 1 study (“Study 2020-0123”) is being conducted by The University of Texas MD Anderson Cancer Center (“MD Anderson”) as part of an ongoing strategic collaboration with Nanobiotix.
  • “NBTXR3 is designed as a product candidate with the potential to improve treatment outcomes for patients with cancer in any setting where radiotherapy is a part of the treatment regimen.
  • “We believe the injection feasibility and favorable safety profile we have observed from the completed dose escalation part of this Phase 1 lung cancer study could pave the way for additional clinical development of NBTXR3 for patients with inoperable, recurrent lung cancer and patients amenable to re-irradiation.”
    The completed dose escalation part of Study 2020-0123 established the recommended Phase 2 dose after determination of injection feasibility and observation of a favorable safety profile.
  • The expansion part of the study, further evaluating safety and early signals of efficacy, is ongoing.

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Retrieved on: 
Tuesday, April 2, 2024
Toxicity, Radiation, Sintilimab, NMPA, Endometrial cancer, Disease, DCR, New Drug Application, Patient, NDA, Breakthrough therapy, Senior, Priority review, HKEX, Dor, IRC, Prognosis, PFS, Pharmaceutical industry

HONG KONG, SHANGHAI, China & FLORHAM PARK, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) and Innovent Biologics, Inc. (“Innovent”) (HKEX:1801) today jointly announce that the New Drug Application (“NDA”) for the combination of fruquintinib and sintilimab for the treatment of patients with advanced endometrial cancer with pMMR1 or non-MSI-H2 tumors that have failed prior systemic therapy but are not candidates for curative surgery or radiation has been accepted and granted priority review by the China National Medical Products Administration (“NMPA”).

Key Points: 
  • The NDA is supported by data from FRUSICA-1, the endometrial cancer registration cohort of a multi-center, open-label Phase II study investigating fruquintinib in combination with sintilimab in endometrial cancer patients who experienced disease recurrence, disease progression or intolerable toxicity with treatment on platinum-based doublet chemotherapy.
  • Data from FRUSICA-1 will be submitted for presentation at an upcoming medical conference.
  • “This is the first regulatory filing for the combination of fruquintinib and the immune checkpoint inhibitor sintilimab.
  • “Endometrial cancer remains one of the most common gynecological malignancies.

Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 28, 2024
AstraZeneca, Exercise, Fortification, New Drug Application, Patient, GBM, CRL, NDA, Menkes, Minocycline, Therapy, Marketing, Radiation, CKPT, Rosacea, Investigational New Drug, Erythema, Safety, BLA, Fortress Biotech, Food, Red, Amyloidosis, Dermatology, Carcinoma, FDA, Hyperhidrosis, Mustang Bio, Menkes disease, PDUFA, Pharmaceutical industry

MIAMI, March 28, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.

Key Points: 
  • Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, said, “In 2023, we built a significant amount of momentum to position our Company to achieve multiple milestones in 2024.
  • In March 2024, the FDA accepted the NDA and has set a PDUFA goal date of November 4, 2024.
  • In December 2023, the FDA issued a complete response letter (“CRL”) for the cosibelimab BLA.
  • Fortress’ consolidated net revenue totaled $84.5 million for the full year ended December 31, 2023, which included $59.7 million in net revenue generated from our marketed dermatology products.

World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain

Retrieved on: 
Tuesday, March 26, 2024
Diagnosis, Biopsy, Sentinel lymph node, Radiation, Prostate cancer, Patient, ASX, SLN, Prostate, Bladder cancer, Hospital, TLX, Lymph node, Health technology, Medtech, AA, Medical imaging

SENSEI® is smaller than an AA battery and designed specifically for robotic-assisted and minimally invasive surgery.

Key Points: 
  • SENSEI® is smaller than an AA battery and designed specifically for robotic-assisted and minimally invasive surgery.
  • The miniature size and proprietary features make the technology ideal for tight surgical spaces such as around the bladder.
  • Radio-guided surgery has historically been limited by the fact that gamma probes are generally only suitable for open surgery.
  • Nynke van den Berg, General Manager Medical Technologies (MedTech) at Telix added, “A first bladder cancer procedure with the SENSEI® drop-in gamma probe is a significant milestone for Telix and the Lightpoint team.

Bestqool Unveils the Key to Optimal Health: The Perfect Duration for Red Light Therapy Sessions

Retrieved on: 
Tuesday, March 26, 2024
Pigment, Health, Radiation, Burns, Fibromyalgia, Cell, Inflammation, Patient, Tissue, Muscle fatigue, Athlete, Arthritis, Light, Wound healing, Skin, Safety, Red light, Low-level laser therapy, Ageing, Medical imaging

Seattle, Washington, March 26, 2024 (GLOBE NEWSWIRE) -- In an exciting development for wellness enthusiasts and health-conscious individuals, Bestqool, has announced its insights into the optimal duration for Red Light Therapy sessions.

Key Points: 
  • Seattle, Washington, March 26, 2024 (GLOBE NEWSWIRE) -- In an exciting development for wellness enthusiasts and health-conscious individuals, Bestqool, has announced its insights into the optimal duration for Red Light Therapy sessions.
  • This revelation promises to enhance the efficacy and safety of Red Light Therapy, a popular and effective treatment that has captivated global attention for its numerous health benefits.
  • How Long Should Red Light Therapy Sessions Last?
  • In pain relief, Red Light therapy duration can last as long as 15 to 30 minutes instead.

American Oncology Network Expands Footprint in Texas with the Addition of Woodlands Cancer Institute in Houston

Retrieved on: 
Tuesday, March 26, 2024
AON, MRCP, Oncology, Partnership, FACP, Radiation, Physician, Health, Nursing

WOODLANDS, Texas, March 26, 2024 (GLOBE NEWSWIRE) -- American Oncology Network (AON) (Nasdaq: AONC), one of the nation’s fastest-growing networks of independent oncology practices, is pleased to announce the opening of Woodlands Cancer Institute and welcomes its physicians to the network.

Key Points: 
  • WOODLANDS, Texas, March 26, 2024 (GLOBE NEWSWIRE) -- American Oncology Network (AON) (Nasdaq: AONC), one of the nation’s fastest-growing networks of independent oncology practices, is pleased to announce the opening of Woodlands Cancer Institute and welcomes its physicians to the network.
  • Woodlands Cancer Institute is AON’s second practice in Texas and first in Montgomery County.
  • The practice specializes in delivering medical oncology, radiation oncology and hematology care and services in a community-based setting.
  • “On behalf of AON, I would like to extend a welcome to Woodlands Cancer Institute and their care team to our growing network of oncology practices,” said Anthony Belott , AON’s chief development officer.

Grafana Labs Unveiled Open Source Project Updates at Annual GrafanaCON Community Conference

Retrieved on: 
Tuesday, April 9, 2024
Professional Services, Data Management, Technology, Data Analytics, Software, Networks, Loki, Cloud, Metric, Radiation, Organization, Plant, Growth, Data science, Entrepreneurship, Science, JAXA, Moon, Integration, Tempo, SLIM, Anomaly, GitHub, Acceleration, SAML, Data, Metadata, Ecosystem, ID, UI, Video game

Grafana Labs, the company behind the world’s most ubiquitous, open and composable operational dashboards, today made three major announcements that build on its commitment to the open source community: the release of Grafana 11.0, Loki 3.0, and Grafana Alloy – the company's open source distribution of the OpenTelemetry Collector.

Key Points: 
  • Grafana Labs, the company behind the world’s most ubiquitous, open and composable operational dashboards, today made three major announcements that build on its commitment to the open source community: the release of Grafana 11.0, Loki 3.0, and Grafana Alloy – the company's open source distribution of the OpenTelemetry Collector.
  • These updates were unveiled during Grafana Labs’ sold-out GrafanaCON community conference in Amsterdam, held in person for the first time in five years.
  • GrafanaCON, originally centered solely on the Grafana project, has evolved this year to include the extended open source observability ecosystem.
  • During the keynote, Grafana Labs CEO Raj Dutt presented the second annual Golden Grot Awards , which recognize dashboards created by community members.

Mirion Dosimetry Services Announces Availability of New InstadoseVUE Wireless Radiation Dosimeter

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Health, Biometrics, Other Health, Nuclear, Radiology, Energy, Oncology, Other Science, Medical Devices, General Health, Hospitals, Health Technology, Science, Radiation, Communication, Risk, VUE, Safety, Multimedia, Medical imaging

Mirion Dosimetry Services , a Mirion Medical company, today announced commercial availability of its innovative new Instadose®VUE wireless dosimeter .

Key Points: 
  • Mirion Dosimetry Services , a Mirion Medical company, today announced commercial availability of its innovative new Instadose®VUE wireless dosimeter .
  • View the full release here: https://www.businesswire.com/news/home/20240408854096/en/
    The Instadose®VUE wireless dosimeter from Mirion Dosimetry Services, a Mirion Medical company.
  • “Launching the InstadoseVUE dosimeter signifies more than just the release of a product; it embodies our vision to redefine radiation safety in workplaces.
  • Electronic display screen for expanded user visibility, engagement, and compliance
    “The InstadoseVUE wireless dosimeter is not just for radiation workers and medical imaging personnel,” says Bart LeClou, VP of International Sales for Mirion Dosimetry Services.

SpaceBilt and Phison Skyrocket to International Space Station in 2025

Retrieved on: 
Monday, April 8, 2024
Aerospace, Hardware, Manufacturing, Data Management, Technology, Radiation, SOC, SSD, Risk, X1, CASIS, International Space Station, Moon, Space Symposium, Linux, Defense Innovation Unit, ISS, Solid-state drive, NVIDIA, ISS National Lab, Integrated circuit, Engineering, Liss, Video game

SpaceBilt Inc., today announced it has partnered with Phison to fly the Large in Space Server (LiSS), the world’s first 100 terabyte plus data storage and edge compute center to the International Space Station (ISS) in 2025.

Key Points: 
  • SpaceBilt Inc., today announced it has partnered with Phison to fly the Large in Space Server (LiSS), the world’s first 100 terabyte plus data storage and edge compute center to the International Space Station (ISS) in 2025.
  • SpaceBilt and partner Novium will provide demonstrations of a mockup space station at the Space Symposium from April 8 - 11, 2024 in Colorado Springs, Colo.
  • Phison is supplying the technical expertise to enable SpaceBilt to access engineering data associated with the performance of the X1 SSD drives in the radiation and vacuum environment of space.
  • Phison’s upcoming SpaceBilt flight to the International Space Station marks a return to space for the company.